0001778016--12-312022Q2false2022-06-3000017780162022-01-012022-06-300001778016us-gaap:MeasurementInputRiskFreeInterestRateMember2020-12-170001778016us-gaap:MeasurementInputPriceVolatilityMember2020-12-170001778016us-gaap:MeasurementInputExercisePriceMember2020-12-170001778016us-gaap:MeasurementInputRiskFreeInterestRateMember2020-09-110001778016us-gaap:MeasurementInputPriceVolatilityMember2020-09-110001778016us-gaap:MeasurementInputExercisePriceMember2020-09-110001778016us-gaap:MeasurementInputMaturityMember2020-12-170001778016us-gaap:MeasurementInputMaturityMember2020-09-110001778016us-gaap:SeriesCPreferredStockMember2020-01-170001778016imab:SeriesCOneConvertiblePreferredStockMember2020-01-170001778016imab:ConvertiblePreferredStockSeriesB2Member2020-01-170001778016us-gaap:CommonStockMember2022-01-012022-06-300001778016imab:SpecialAwardsMemberimab:ShareIncentivePlanTwoThousandTwentyMember2020-01-012020-12-310001778016imab:ImabHangzhouMemberimab:ManagementHoldcoMember2021-01-012021-12-310001778016us-gaap:PrivatePlacementMember2020-09-032020-09-030001778016us-gaap:RetainedEarningsMember2022-06-300001778016us-gaap:AdditionalPaidInCapitalMember2022-06-300001778016us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300001778016us-gaap:RetainedEarningsMember2021-12-310001778016us-gaap:AdditionalPaidInCapitalMember2021-12-310001778016us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001778016us-gaap:RetainedEarningsMember2021-06-300001778016us-gaap:AdditionalPaidInCapitalMember2021-06-300001778016us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300001778016us-gaap:RetainedEarningsMember2020-12-310001778016us-gaap:AdditionalPaidInCapitalMember2020-12-310001778016us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001778016us-gaap:CommonStockMember2022-06-300001778016us-gaap:CommonStockMember2021-12-310001778016us-gaap:CommonStockMember2021-06-300001778016us-gaap:CommonStockMember2020-12-310001778016dei:AdrMemberus-gaap:IPOMember2020-01-170001778016imab:EmployeeStockOptionPlanMember2022-06-300001778016dei:AdrMemberus-gaap:PrivatePlacementMember2020-09-030001778016dei:AdrMember2020-02-100001778016imab:DrzangMemberus-gaap:EmployeeStockOptionMemberimab:TwentyEighteenEmployeeStockOptionPlanMember2019-12-252019-12-250001778016imab:TwentyNineteenShareIncentivePlanMember2021-01-012021-12-310001778016imab:TwentyTwentyTwoEmployeeStockOptionPlanMember2022-01-012022-06-300001778016imab:TwentySeventeenEmployeeStockOptionPlanMember2021-01-012021-12-310001778016imab:TwentyEighteenEmployeeStockOptionPlanMember2021-01-012021-12-310001778016imab:ShareIncentivePlanTwoThousandTwentyOneMember2021-01-012021-12-310001778016imab:ShareIncentivePlanTwoThousandTwentyMember2021-01-012021-12-310001778016imab:TwentyNineteenShareIncentivePlanMember2020-01-012020-12-310001778016imab:FoundersMemberus-gaap:EmployeeStockOptionMemberimab:TwentySeventeenEmployeeStockOptionPlanMember2019-12-252019-12-250001778016imab:TwentySeventeenEmployeeStockOptionPlanMember2022-01-012022-06-300001778016imab:TwentyEighteenEmployeeStockOptionPlanMember2022-01-012022-06-300001778016imab:TwentyNineteenShareIncentivePlanMember2022-06-300001778016imab:ShareIncentivePlanTwoThousandTwentyMember2022-06-300001778016imab:TwentySeventeenEmployeeStockOptionPlanMember2021-12-310001778016imab:TwentyNineteenShareIncentivePlanMember2021-12-310001778016imab:TwentyEighteenEmployeeStockOptionPlanMember2021-12-310001778016imab:ShareIncentivePlanTwoThousandTwentyOneMember2021-12-310001778016imab:ShareIncentivePlanTwoThousandTwentyMember2021-12-310001778016imab:TwentySeventeenEmployeeStockOptionPlanMember2022-06-300001778016imab:TwentyEighteenEmployeeStockOptionPlanMember2022-06-300001778016us-gaap:RestrictedStockUnitsRSUMemberimab:TwentyTwentyTwoEmployeeStockOptionPlanMember2022-06-170001778016imab:TwentyTwentyTwoEmployeeStockOptionPlanMember2022-06-170001778016us-gaap:RestrictedStockUnitsRSUMemberimab:ShareIncentivePlanTwoThousandTwentyOneMember2021-05-280001778016imab:ShareIncentivePlanTwoThousandTwentyOneMember2021-05-280001778016us-gaap:RestrictedStockUnitsRSUMember2020-07-150001778016imab:ShareIncentivePlanTwoThousandTwentyMember2020-07-150001778016imab:TwentyEighteenEmployeeStockOptionPlanMember2019-12-310001778016imab:TwentyNineteenShareIncentivePlanMember2019-10-290001778016imab:TwentyEighteenEmployeeStockOptionPlanMember2019-02-220001778016imab:TwentySeventeenEmployeeStockOptionPlanMember2017-10-310001778016imab:ShareIncentivePlanTwoThousandTwentyOneMember2022-01-012022-06-300001778016imab:ShareIncentivePlanTwoThousandTwentyOneMember2021-01-012021-06-300001778016imab:ShareIncentivePlanTwoThousandTwentyMember2021-01-012021-06-300001778016us-gaap:RestrictedStockUnitsRSUMemberimab:ShareIncentivePlanTwoThousandTwentyOneMember2021-01-012021-12-310001778016us-gaap:RestrictedStockUnitsRSUMemberimab:ShareIncentivePlanTwoThousandTwentyMember2021-01-012021-12-310001778016us-gaap:RestrictedStockUnitsRSUMemberimab:ShareIncentivePlanTwoThousandTwentyOneMember2022-06-300001778016us-gaap:RestrictedStockUnitsRSUMemberimab:ShareIncentivePlanTwoThousandTwentyMember2022-06-300001778016us-gaap:RestrictedStockUnitsRSUMemberimab:ShareIncentivePlanTwoThousandTwentyOneMember2021-12-310001778016us-gaap:RestrictedStockUnitsRSUMemberimab:ShareIncentivePlanTwoThousandTwentyMember2021-12-310001778016imab:ThirdOneThirdPortionMemberus-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2021-05-282021-05-280001778016imab:ThirdOneThirdPortionMemberus-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember2021-05-282021-05-280001778016imab:ThirdOneThirdPortionMemberus-gaap:RestrictedStockUnitsRSUMemberimab:ShareBasedCompensationTrancheFourMember2021-05-282021-05-280001778016imab:SecondOneThirdPortionMemberus-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2021-05-282021-05-280001778016imab:SharePriceBasedAwardsMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2021-05-282021-05-280001778016imab:SharePriceBasedAwardsMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2021-05-282021-05-280001778016imab:ShareIncentivePlanTwoThousandTwentyOneMember2021-05-282021-05-280001778016imab:OnePerformanceConditionMember2021-05-282021-05-280001778016imab:ThirdOneThirdPortionMemberus-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2020-07-152020-07-150001778016imab:ThirdOneThirdPortionMemberus-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember2020-07-152020-07-150001778016imab:ThirdOneThirdPortionMemberus-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2020-07-152020-07-150001778016imab:ThirdOneThirdPortionMemberus-gaap:RestrictedStockUnitsRSUMemberimab:TwoPerformanceConditionsMember2020-07-152020-07-150001778016imab:ThirdOneThirdPortionMemberus-gaap:RestrictedStockUnitsRSUMemberimab:ThreePerformanceConditionsMember2020-07-152020-07-150001778016imab:ThirdOneThirdPortionMemberus-gaap:RestrictedStockUnitsRSUMemberimab:ShareBasedCompensationTrancheFourMember2020-07-152020-07-150001778016imab:ThirdOneThirdPortionMemberus-gaap:RestrictedStockUnitsRSUMemberimab:OnePerformanceConditionMember2020-07-152020-07-150001778016imab:ThirdOneThirdPortionMemberus-gaap:RestrictedStockUnitsRSUMemberimab:FourPerformanceConditionsMember2020-07-152020-07-150001778016us-gaap:EmployeeStockOptionMemberimab:ShareIncentivePlanTwoThousandTwentyMember2020-07-152020-07-150001778016imab:TwentyEighteenEmployeeStockOptionPlanMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2019-02-222019-02-220001778016imab:TwentyEighteenEmployeeStockOptionPlanMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2019-02-222019-02-220001778016us-gaap:EmployeeStockOptionMemberimab:TwentySeventeenEmployeeStockOptionPlanMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2017-10-012017-10-310001778016us-gaap:EmployeeStockOptionMemberimab:TwentySeventeenEmployeeStockOptionPlanMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2017-10-012017-10-310001778016imab:SharePriceBasedAwardsMember2021-05-282021-05-280001778016us-gaap:EmployeeStockOptionMemberimab:TwentyEighteenEmployeeStockOptionPlanMember2019-02-222019-02-220001778016us-gaap:EmployeeStockOptionMemberimab:TwentySeventeenEmployeeStockOptionPlanMember2017-10-012017-10-310001778016us-gaap:EmployeeStockOptionMemberimab:TwentySeventeenEmployeeStockOptionPlanMember2022-01-012022-06-300001778016us-gaap:EmployeeStockOptionMemberimab:TwentyNineteenShareIncentivePlanMember2022-01-012022-06-300001778016us-gaap:EmployeeStockOptionMemberimab:TwentyEighteenEmployeeStockOptionPlanMember2022-01-012022-06-300001778016imab:SpecialAwardsMemberimab:ShareIncentivePlanTwoThousandTwentyMember2022-01-012022-06-300001778016imab:PaycheckProtectionMember2022-01-012022-06-300001778016imab:PaycheckProtectionMember2021-01-012021-06-300001778016imab:SupplyOfInvestigationalProductsMember2022-01-012022-06-300001778016imab:StrategicAllianceAgreementWithPtKalbeGenexineBiologicsMember2022-01-012022-06-300001778016imab:LicensingAndCollaborationMember2022-01-012022-06-300001778016imab:CspcMemberimab:LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMember2021-01-012021-12-310001778016imab:StrategicAllianceAgreementWithPtKalbeGenexineBiologicsMember2021-01-012021-12-310001778016imab:CspcMemberimab:LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMember2021-01-012021-06-300001778016imab:LicensingAndCollaborationMember2021-01-012021-06-300001778016imab:CspcMemberimab:LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMember2020-01-012020-12-310001778016imab:CspcMemberimab:LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMember2019-01-012019-12-310001778016us-gaap:ResearchAndDevelopmentExpenseMemberimab:ABLBioMemberimab:CollaborationAgreementWithABLBioMember2022-01-012022-06-300001778016imab:ABLBioMemberus-gaap:ResearchAndDevelopmentExpenseMemberimab:CollaborationAgreementWithABLBioMember2022-01-012022-06-300001778016us-gaap:OperatingExpenseMemberimab:CollaborationAgreementsWithTraconPharmaceuticalsIncMember2022-01-012022-06-300001778016us-gaap:ResearchAndDevelopmentExpenseMemberimab:ABLBioMemberimab:CollaborationAgreementWithABLBioMember2021-01-012021-06-300001778016imab:GenexineIncMemberus-gaap:ResearchAndDevelopmentExpenseMemberimab:LicensingAgreementWithGenexineIncMember2021-01-012021-06-300001778016imab:ABLBioMemberus-gaap:ResearchAndDevelopmentExpenseMemberimab:CollaborationAgreementWithABLBioMember2021-01-012021-06-300001778016us-gaap:OperatingExpenseMemberimab:CollaborationAgreementsWithTraconPharmaceuticalsIncMember2021-01-012021-06-300001778016imab:GenexineIncMemberimab:LicensingAgreementWithGenexineIncMember2021-01-012021-06-300001778016imab:Study2Memberimab:AbbVieMember2020-12-102020-12-100001778016imab:Study1Memberimab:AbbVieMember2020-12-102020-12-100001778016us-gaap:OperatingExpenseMemberimab:CollaborationAgreementsWithTraconPharmaceuticalsIncMember2020-01-012020-12-310001778016us-gaap:OperatingExpenseMemberimab:CollaborationAgreementsWithTraconPharmaceuticalsIncMember2019-01-012019-12-310001778016srt:MinimumMemberimab:SoftwareMember2022-01-012022-06-300001778016srt:MinimumMemberimab:LaboratoryEquipmentMember2022-01-012022-06-300001778016srt:MaximumMemberimab:SoftwareMember2022-01-012022-06-300001778016srt:MaximumMemberimab:LaboratoryEquipmentMember2022-01-012022-06-300001778016us-gaap:TransportationEquipmentMember2022-01-012022-06-300001778016imab:OfficeFurnitureAndEquipmentMember2022-01-012022-06-300001778016us-gaap:TransportationEquipmentMember2022-06-300001778016us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2022-06-300001778016us-gaap:OfficeEquipmentMember2022-06-300001778016us-gaap:LeaseholdImprovementsMember2022-06-300001778016imab:LaboratoryEquipmentMember2022-06-300001778016us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2021-12-310001778016us-gaap:OfficeEquipmentMember2021-12-310001778016us-gaap:LeaseholdImprovementsMember2021-12-310001778016imab:LaboratoryEquipmentMember2021-12-310001778016srt:MaximumMemberimab:AbbVieMember2020-09-032020-09-030001778016imab:ClinicalMilestonesMemberimab:AbbVieMember2020-09-032020-09-030001778016imab:CspcMemberimab:LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMember2019-09-012019-09-300001778016imab:CspcMemberimab:LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMember2019-02-012019-02-280001778016imab:InvestorWarrantsMemberdei:AdrMember2020-09-032020-09-030001778016dei:AdrMember2020-02-102020-02-100001778016dei:AdrMemberus-gaap:IPOMember2020-01-172020-01-170001778016imab:SeriesAConvertiblePreferredStockMember2020-01-170001778016imab:ConvertiblePreferredStockSeriesBOneUponConversionMember2020-01-170001778016imab:ConvertiblePreferredStockSeriesBMember2020-01-170001778016us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-06-300001778016us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-06-300001778016us-gaap:RetainedEarningsMember2022-01-012022-06-300001778016us-gaap:RetainedEarningsMember2021-01-012021-06-300001778016imab:ImabHangzhouMemberimab:ManagementHoldcoMember2022-01-012022-06-300001778016imab:ImabHangzhouMemberimab:IMabHangzhouShareBasedCompensationMember2022-01-012022-06-300001778016imab:ImabHangzhouMemberimab:HLBVMethodMember2022-01-012022-06-300001778016imab:ImabHangzhouMemberimab:GroupsShareBasedCompensationMember2022-01-012022-06-300001778016imab:PartnershipAgreementMember2022-01-012022-06-300001778016imab:ImabHangzhouMemberimab:ManagementHoldcoMember2021-01-012021-06-300001778016imab:ImabHangzhouMemberimab:IMabHangzhouShareBasedCompensationMember2021-01-012021-06-300001778016imab:ImabHangzhouMemberimab:HLBVMethodMember2021-01-012021-06-300001778016imab:ImabHangzhouMemberimab:GroupsShareBasedCompensationMember2021-01-012021-06-300001778016imab:PartnershipAgreementMember2021-01-012021-06-300001778016imab:LongTermInvestmentUnderEquityMethodMember2022-01-012022-06-300001778016imab:LongTermInvestmentUnderEquityMethodMember2021-01-012021-06-300001778016imab:PeoplesBankOfChinaMember2022-06-300001778016imab:FederalReserveBankOfNewYorkMember2022-06-300001778016imab:PeoplesBankOfChinaMember2021-12-310001778016srt:MinimumMemberus-gaap:ContractBasedIntangibleAssetsMember2022-01-012022-06-300001778016srt:MaximumMemberus-gaap:ContractBasedIntangibleAssetsMember2022-01-012022-06-300001778016imab:IprAndDTj101Member2022-06-300001778016imab:IprAndDTj101Member2021-12-310001778016imab:TJ103Member2022-06-300001778016imab:TJ103Member2021-12-310001778016us-gaap:InvestmentsMember2022-06-300001778016imab:PutRightLiabilitiesMember2022-06-300001778016us-gaap:InvestmentsMember2021-12-310001778016imab:PutRightLiabilitiesMember2021-12-310001778016imab:PartnershipAgreementMember2022-06-300001778016imab:PartnershipAgreementMember2021-12-310001778016imab:ImabHangzhouMember2021-12-310001778016imab:PartnershipAgreementMember2021-08-3100017780162020-09-012020-09-300001778016imab:ZhejiangTianliPharmaceuticalSalesCoLtdMember2022-06-300001778016imab:IMabtianjinMember2022-06-300001778016imab:IMabShanghaiMember2022-06-300001778016imab:ImabHangzhouMember2022-06-300001778016imab:ImabbiopharmaUsLtdMember2022-06-300001778016imab:IMabBiopharmaHongKongLimitedMember2022-06-300001778016imab:ImabHangzhouMemberimab:ImabHongKongMember2020-12-310001778016imab:ImabHangzhouMemberimab:EsopHoldcoMember2020-12-310001778016imab:ImabHangzhouMemberimab:DomesticInvestorsMember2020-12-310001778016dei:AdrMember2022-01-012022-06-300001778016dei:AdrMember2021-01-012021-06-300001778016imab:ImabHangzhouMember2022-06-300001778016imab:AbbVieMember2022-01-012022-06-300001778016imab:AbbVieMember2021-01-012021-12-310001778016imab:AbbVieMember2021-01-012021-06-300001778016imab:EverestsMemberimab:CollaborationAgreementWithEverestMember2020-01-170001778016us-gaap:SeriesCPreferredStockMember2020-01-172020-01-170001778016imab:SeriesCOneConvertiblePreferredStockMember2020-01-172020-01-170001778016imab:SeriesAConvertiblePreferredStockMember2020-01-172020-01-170001778016imab:ConvertiblePreferredStockSeriesBOneUponConversionMember2020-01-172020-01-170001778016imab:ConvertiblePreferredStockSeriesBMember2020-01-172020-01-170001778016imab:ConvertiblePreferredStockSeriesB2Member2020-01-172020-01-170001778016imab:CspcMemberimab:LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMember2018-12-310001778016imab:AbbVieMember2022-06-300001778016imab:AbbVieMember2020-12-310001778016imab:PartnershipAgreementMember2021-07-310001778016imab:ImabHangzhouMemberimab:ManagementHoldcoMember2020-12-310001778016imab:ImabHongKongMember2021-06-300001778016imab:ImabHangzhouMember2021-06-300001778016imab:DomesticInvestorsMember2021-06-300001778016imab:ImabHongKongMember2020-12-310001778016imab:ImabHangzhouMember2020-12-310001778016imab:DomesticInvestorsMember2020-12-3100017780162019-12-3100017780162018-12-310001778016imab:FoundersMemberus-gaap:EmployeeStockOptionMemberimab:TwentySeventeenEmployeeStockOptionPlanMember2019-12-250001778016imab:DrzangMemberus-gaap:EmployeeStockOptionMemberimab:TwentyEighteenEmployeeStockOptionPlanMember2019-12-250001778016imab:InvestorWarrantsMemberdei:AdrMember2020-09-030001778016imab:InvestorWarrantsMember2020-09-030001778016imab:WarrantsToPurchaseOrdinarySharesMember2020-12-170001778016imab:WarrantsToPurchaseOrdinarySharesMember2020-09-1100017780162021-06-3000017780162020-12-310001778016imab:ImabHangzhouMember2022-06-300001778016imab:TasgenGroupMember2017-07-150001778016us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOtherMember2022-06-300001778016imab:ImabHangzhouMember2022-06-300001778016us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOtherMember2021-12-310001778016imab:ImabHangzhouMember2021-12-310001778016us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-06-300001778016us-gaap:EmployeeStockOptionMember2022-01-012022-06-300001778016us-gaap:WarrantMember2021-01-012021-06-300001778016us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-06-300001778016us-gaap:EmployeeStockOptionMember2021-01-012021-06-300001778016imab:TJ103Member2022-01-012022-06-300001778016imab:TJ103Member2021-01-012021-06-300001778016us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ResearchAndDevelopmentExpenseMemberimab:ShareIncentivePlanTwoThousandTwentyOneMember2022-01-012022-06-300001778016us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ResearchAndDevelopmentExpenseMemberimab:ShareIncentivePlanTwoThousandTwentyMember2022-01-012022-06-300001778016us-gaap:RestrictedStockUnitsRSUMemberus-gaap:GeneralAndAdministrativeExpenseMemberimab:ShareIncentivePlanTwoThousandTwentyOneMember2022-01-012022-06-300001778016us-gaap:RestrictedStockUnitsRSUMemberus-gaap:GeneralAndAdministrativeExpenseMemberimab:ShareIncentivePlanTwoThousandTwentyMember2022-01-012022-06-300001778016us-gaap:RestrictedStockUnitsRSUMemberimab:EquityInLossOfAnAffiliateMemberimab:ShareIncentivePlanTwoThousandTwentyMember2022-01-012022-06-300001778016us-gaap:EmployeeStockOptionMemberus-gaap:ResearchAndDevelopmentExpenseMemberimab:ShareIncentivePlanTwoThousandTwentyOneMember2022-01-012022-06-300001778016us-gaap:EmployeeStockOptionMemberus-gaap:ResearchAndDevelopmentExpenseMemberimab:ShareIncentivePlanTwoThousandTwentyMember2022-01-012022-06-300001778016us-gaap:EmployeeStockOptionMemberus-gaap:GeneralAndAdministrativeExpenseMemberimab:ShareIncentivePlanTwoThousandTwentyOneMember2022-01-012022-06-300001778016us-gaap:EmployeeStockOptionMemberus-gaap:GeneralAndAdministrativeExpenseMemberimab:ShareIncentivePlanTwoThousandTwentyMember2022-01-012022-06-300001778016us-gaap:EmployeeStockOptionMemberimab:EquityInLossOfAnAffiliateMemberimab:ShareIncentivePlanTwoThousandTwentyMember2022-01-012022-06-300001778016us-gaap:RestrictedStockUnitsRSUMemberimab:ShareIncentivePlanTwoThousandTwentyOneMember2022-01-012022-06-300001778016us-gaap:RestrictedStockUnitsRSUMemberimab:ShareIncentivePlanTwoThousandTwentyMember2022-01-012022-06-300001778016us-gaap:ResearchAndDevelopmentExpenseMemberimab:TwentyNineteenShareIncentivePlanMember2022-01-012022-06-300001778016us-gaap:GeneralAndAdministrativeExpenseMemberimab:TwentyNineteenShareIncentivePlanMember2022-01-012022-06-300001778016us-gaap:EmployeeStockOptionMemberimab:ShareIncentivePlanTwoThousandTwentyOneMember2022-01-012022-06-300001778016us-gaap:EmployeeStockOptionMemberimab:ShareIncentivePlanTwoThousandTwentyMember2022-01-012022-06-300001778016imab:EquityInLossOfAnAffiliateMemberimab:TwentyNineteenShareIncentivePlanMember2022-01-012022-06-300001778016us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-06-300001778016us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-06-300001778016imab:TwentyNineteenShareIncentivePlanMember2022-01-012022-06-300001778016imab:EquityInLossOfAnAffiliateMember2022-01-012022-06-300001778016us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ResearchAndDevelopmentExpenseMemberimab:ShareIncentivePlanTwoThousandTwentyOneMember2021-01-012021-06-300001778016us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ResearchAndDevelopmentExpenseMemberimab:ShareIncentivePlanTwoThousandTwentyMember2021-01-012021-06-300001778016us-gaap:RestrictedStockUnitsRSUMemberus-gaap:GeneralAndAdministrativeExpenseMemberimab:ShareIncentivePlanTwoThousandTwentyOneMember2021-01-012021-06-300001778016us-gaap:RestrictedStockUnitsRSUMemberus-gaap:GeneralAndAdministrativeExpenseMemberimab:ShareIncentivePlanTwoThousandTwentyMember2021-01-012021-06-300001778016us-gaap:RestrictedStockUnitsRSUMemberimab:EquityInLossOfAnAffiliateMemberimab:ShareIncentivePlanTwoThousandTwentyMember2021-01-012021-06-300001778016us-gaap:EmployeeStockOptionMemberus-gaap:ResearchAndDevelopmentExpenseMemberimab:ShareIncentivePlanTwoThousandTwentyOneMember2021-01-012021-06-300001778016us-gaap:EmployeeStockOptionMemberus-gaap:ResearchAndDevelopmentExpenseMemberimab:ShareIncentivePlanTwoThousandTwentyMember2021-01-012021-06-300001778016us-gaap:EmployeeStockOptionMemberus-gaap:GeneralAndAdministrativeExpenseMemberimab:ShareIncentivePlanTwoThousandTwentyMember2021-01-012021-06-300001778016us-gaap:EmployeeStockOptionMemberimab:EquityInLossOfAnAffiliateMemberimab:ShareIncentivePlanTwoThousandTwentyMember2021-01-012021-06-300001778016imab:SpecialAwardsMemberus-gaap:ResearchAndDevelopmentExpenseMemberimab:ShareIncentivePlanTwoThousandTwentyMember2021-01-012021-06-300001778016imab:SpecialAwardsMemberus-gaap:GeneralAndAdministrativeExpenseMemberimab:ShareIncentivePlanTwoThousandTwentyMember2021-01-012021-06-300001778016imab:SpecialAwardsMemberimab:EquityInLossOfAnAffiliateMemberimab:ShareIncentivePlanTwoThousandTwentyMember2021-01-012021-06-300001778016us-gaap:RestrictedStockUnitsRSUMemberimab:ShareIncentivePlanTwoThousandTwentyOneMember2021-01-012021-06-300001778016us-gaap:RestrictedStockUnitsRSUMemberimab:ShareIncentivePlanTwoThousandTwentyMember2021-01-012021-06-300001778016us-gaap:ResearchAndDevelopmentExpenseMemberimab:TwentySeventeenEmployeeStockOptionPlanMember2021-01-012021-06-300001778016us-gaap:ResearchAndDevelopmentExpenseMemberimab:TwentyNineteenShareIncentivePlanMember2021-01-012021-06-300001778016us-gaap:ResearchAndDevelopmentExpenseMemberimab:TwentyEighteenEmployeeStockOptionPlanMember2021-01-012021-06-300001778016us-gaap:GeneralAndAdministrativeExpenseMemberimab:TwentySeventeenEmployeeStockOptionPlanMember2021-01-012021-06-300001778016us-gaap:GeneralAndAdministrativeExpenseMemberimab:TwentyNineteenShareIncentivePlanMember2021-01-012021-06-300001778016us-gaap:GeneralAndAdministrativeExpenseMemberimab:TwentyEighteenEmployeeStockOptionPlanMember2021-01-012021-06-300001778016us-gaap:EmployeeStockOptionMemberimab:ShareIncentivePlanTwoThousandTwentyOneMember2021-01-012021-06-300001778016us-gaap:EmployeeStockOptionMemberimab:ShareIncentivePlanTwoThousandTwentyMember2021-01-012021-06-300001778016imab:SpecialAwardsMemberimab:ShareIncentivePlanTwoThousandTwentyMember2021-01-012021-06-300001778016imab:EquityInLossOfAnAffiliateMemberimab:TwentySeventeenEmployeeStockOptionPlanMember2021-01-012021-06-300001778016imab:EquityInLossOfAnAffiliateMemberimab:TwentyNineteenShareIncentivePlanMember2021-01-012021-06-300001778016imab:EquityInLossOfAnAffiliateMemberimab:TwentyEighteenEmployeeStockOptionPlanMember2021-01-012021-06-300001778016us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-06-300001778016us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-06-300001778016imab:TwentySeventeenEmployeeStockOptionPlanMember2021-01-012021-06-300001778016imab:TwentyNineteenShareIncentivePlanMember2021-01-012021-06-300001778016imab:TwentyEighteenEmployeeStockOptionPlanMember2021-01-012021-06-300001778016imab:EquityInLossOfAnAffiliateMember2021-01-012021-06-300001778016srt:MinimumMember2022-01-012022-06-300001778016srt:MaximumMember2022-01-012022-06-300001778016srt:MaximumMemberimab:StrategicAllianceAgreementWithPtKalbeGenexineBiologicsMember2020-03-012020-03-310001778016imab:AbbVieMember2020-01-012020-12-310001778016imab:MorphoSysAGMemberus-gaap:ResearchAndDevelopmentExpenseMemberimab:LicensingAgreementWithMorphosysAgMember2022-01-012022-06-300001778016imab:OtherInLicensingArrangementMember2022-01-012022-06-300001778016imab:MorphoSysAGMemberus-gaap:ResearchAndDevelopmentExpenseMemberimab:LicensingAgreementWithMorphosysAgMember2021-01-012021-12-310001778016imab:AbbVieMember2020-09-032020-09-030001778016imab:MacroGenicsMemberus-gaap:ResearchAndDevelopmentExpenseMemberimab:LicensingAgreementWithMacroGenicsMember2019-01-012019-12-310001778016imab:MorphosysMemberus-gaap:ResearchAndDevelopmentExpenseMemberimab:LicensingAgreementsWithMorphosysMember2018-01-012018-12-310001778016imab:MorphoSysAGMemberus-gaap:ResearchAndDevelopmentExpenseMemberimab:LicensingAgreementWithMorphosysAgMember2018-01-012018-12-310001778016imab:GenexineIncMemberus-gaap:ResearchAndDevelopmentExpenseMemberimab:LicensingAgreementWithGenexineIncMember2018-01-012018-01-310001778016imab:MorphosysMemberus-gaap:ResearchAndDevelopmentExpenseMemberimab:LicensingAgreementWithMorphosysAgMember2017-01-012017-12-310001778016imab:MorphoSysAGMemberus-gaap:ResearchAndDevelopmentExpenseMemberimab:LicensingAgreementWithMorphosysAgMember2017-01-012017-12-310001778016imab:LemzoparlimabLicenseMemberimab:AbbVieMember2022-01-012022-06-300001778016imab:LemzoparlimabLicenseMemberimab:AbbVieMember2021-01-012021-12-310001778016imab:AbbVieMember2020-12-102020-12-100001778016imab:MacroGenicsMemberus-gaap:SubsequentEventMemberimab:LicensingAgreementWithMacroGenicsMember2022-08-292022-08-290001778016us-gaap:GeneralAndAdministrativeExpenseMemberimab:CollaborationAgreementsWithTraconPharmaceuticalsIncMember2021-06-300001778016imab:CollaborationAgreementsWithTraconPharmaceuticalsIncMember2021-02-280001778016imab:ShareIncentivePlanTwoThousandTwentyMember2022-01-012022-06-300001778016imab:ShareIncentivePlanTwoThousandTwentyOneMember2022-06-300001778016imab:ShareIncentivePlanTwoThousandTwentyMember2021-06-300001778016imab:ShareIncentivePlanTwoThousandTwentyOneMember2021-06-300001778016imab:CspcMemberimab:LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMember2022-01-312022-01-310001778016imab:CspcMemberimab:LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMember2022-01-012022-06-300001778016imab:SecondMilestoneMemberimab:MorphosysMemberimab:LicensingAgreementsWithMorphosysMember2021-01-012021-01-310001778016imab:SecondMilestoneMemberimab:LicensingAgreementsWithMorphosysMember2021-01-012021-01-310001778016imab:ImabHangzhouMemberimab:DomesticInvestorsMember2020-09-150001778016imab:ImabHangzhouMember2020-09-150001778016imab:ImabHangzhouMember2019-06-160001778016imab:ImabHangzhouMemberimab:ManagementHoldcoMember2020-09-150001778016imab:ImabHangzhouMemberimab:EsopHoldcoMember2020-09-150001778016us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001778016us-gaap:FairValueMeasurementsRecurringMember2022-06-300001778016us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001778016us-gaap:FairValueMeasurementsRecurringMember2021-12-310001778016us-gaap:AdditionalPaidInCapitalMember2022-01-012022-06-3000017780162021-11-3000017780162020-04-012020-04-300001778016dei:AdrMemberus-gaap:PrivatePlacementMember2020-09-032020-09-030001778016imab:CollaborationAgreementWithInvestorsMember2020-09-032020-09-030001778016imab:ImabHangzhouMember2021-12-310001778016imab:BoardOfDirectorsMemberdei:AdrMember2020-07-150001778016imab:GenexineIncMemberimab:Gxi7Memberimab:LicensingAgreementWithGenexineIncMember2018-01-012018-01-310001778016imab:MorphosysMemberus-gaap:ResearchAndDevelopmentExpenseMemberimab:LicensingAgreementsWithMorphosysMember2021-01-012021-06-300001778016imab:ImabHangzhouMember2022-01-012022-06-300001778016imab:ThirdOneThirdPortionMemberus-gaap:RestrictedStockUnitsRSUMemberimab:ShareIncentivePlanTwoThousandTwentyMember2020-07-152020-07-150001778016imab:RegulatoryMilestoneMemberimab:MacroGenicsMembersrt:MaximumMemberus-gaap:LicensingAgreementsMemberimab:LicensingAgreementWithMacroGenicsMember2022-01-012022-06-300001778016imab:DevelopmentMilestoneMembersrt:MaximumMemberimab:MacroGenicsMemberimab:LicensingAgreementWithMacroGenicsMember2022-01-012022-06-300001778016imab:SecondMilestoneMemberimab:LemzoparlimabLicenseMemberimab:AbbVieMember2022-01-012022-06-300001778016imab:GenexineIncMemberus-gaap:ResearchAndDevelopmentExpenseMemberimab:LicensingAgreementWithGenexineIncMember2022-01-012022-06-300001778016imab:GenexineIncMemberimab:Gxi7Memberimab:LicensingAgreementWithGenexineIncMember2022-01-012022-06-300001778016imab:FirstMilestoneMemberimab:LemzoparlimabLicenseMemberimab:AbbVieMember2022-01-012022-06-300001778016imab:SalesMilestonesMemberimab:OtherInLicensingArrangementMember2022-01-012022-06-300001778016imab:MorphosysMemberimab:LicensingAgreementsWithMorphosysMember2022-01-012022-06-300001778016imab:MacroGenicsMemberimab:LicensingAgreementWithMacroGenicsMember2022-01-012022-06-300001778016imab:GenexineIncMemberimab:LicensingAgreementWithGenexineIncMember2022-01-012022-06-300001778016imab:GenexineIncMemberimab:LicensingAgreementWithGenexineIncMember2022-01-012022-06-300001778016imab:DevelopmentMilestoneMemberimab:OtherInLicensingArrangementMember2022-01-012022-06-300001778016imab:FirstMilestoneMemberimab:MacroGenicsMemberimab:LicensingAgreementWithMacroGenicsMember2021-09-012021-09-300001778016imab:SecondMilestoneMemberimab:LemzoparlimabLicenseMemberimab:AbbVieMember2021-01-012021-12-310001778016imab:FirstMilestoneMemberimab:LemzoparlimabLicenseMemberimab:AbbVieMember2021-01-012021-12-310001778016imab:GenexineIncMemberimab:LicensingAgreementWithGenexineIncMember2021-01-012021-12-310001778016imab:MacroGenicsMemberus-gaap:ResearchAndDevelopmentExpenseMemberimab:LicensingAgreementWithMacroGenicsMember2021-01-012021-06-300001778016imab:OtherInLicensingArrangementMember2021-01-012021-06-300001778016imab:MorphosysMemberus-gaap:ResearchAndDevelopmentExpenseMemberimab:LicensingAgreementsWithMorphosysMember2020-01-012020-12-310001778016imab:MacroGenicsMemberus-gaap:ResearchAndDevelopmentExpenseMemberimab:LicensingAgreementWithMacroGenicsMember2020-01-012020-12-310001778016imab:MorphoSysAGMemberus-gaap:ResearchAndDevelopmentExpenseMemberimab:LicensingAgreementWithMorphosysAgMember2019-01-012019-12-310001778016imab:MorphosysMemberimab:LicensingAgreementsWithMorphosysMember2019-01-012019-12-310001778016imab:CspcMemberimab:LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMember2018-01-012018-12-310001778016imab:MorphoSysAGMemberimab:LicensingAgreementWithMorphosysAgMember2017-11-172017-11-170001778016imab:AbbVieMember2021-03-310001778016imab:SecondOneThirdPortionMemberus-gaap:RestrictedStockUnitsRSUMemberimab:ShareIncentivePlanTwoThousandTwentyOneMember2021-05-282021-05-280001778016imab:SecondOneThirdPortionMemberus-gaap:RestrictedStockUnitsRSUMemberimab:ShareIncentivePlanTwoThousandTwentyMember2020-07-152020-07-150001778016imab:SecondClosingPeriodMemberimab:HillhouseEntitiesMember2020-12-172020-12-170001778016imab:FirstClosingPeriodMemberimab:HillhouseEntitiesMember2020-09-112020-09-110001778016us-gaap:InvestmentsMember2022-01-012022-06-300001778016imab:PutRightLiabilitiesMember2022-01-012022-06-3000017780162021-01-012021-12-310001778016imab:ImabHangzhouMember2021-06-300001778016srt:MaximumMemberus-gaap:SubsequentEventMemberimab:AmendmentToOriginalLicensingAndCollaborationAgreementMember2022-07-012022-12-3100017780162020-09-032020-09-030001778016imab:ABLBioMemberus-gaap:OperatingExpenseMemberimab:CollaborationAgreementWithABLBioMember2022-01-012022-06-300001778016imab:JumpcanAgreementMember2021-01-012021-12-310001778016imab:ABLBioMemberus-gaap:OperatingExpenseMemberimab:CollaborationAgreementWithABLBioMember2021-01-012021-06-300001778016imab:Study2Memberimab:AbbVieMember2022-01-012022-06-300001778016imab:Study1Memberimab:AbbVieMember2022-01-012022-06-300001778016imab:Study2Memberimab:AbbVieMember2021-01-012021-06-300001778016imab:Study1Memberimab:AbbVieMember2021-01-012021-06-300001778016imab:Study2Memberimab:AbbVieMember2020-01-012020-12-310001778016imab:Study1Memberimab:AbbVieMember2020-01-012020-12-310001778016us-gaap:InvestorMember2019-10-290001778016dei:AdrMemberus-gaap:OverAllotmentOptionMember2020-02-100001778016imab:HillhouseEntitiesMember2022-01-012022-06-300001778016imab:WarrantsToPurchaseOrdinarySharesMember2020-12-172020-12-170001778016imab:WarrantsToPurchaseOrdinarySharesMember2020-09-112020-09-110001778016imab:ImabHangzhouMemberimab:DomesticInvestorsMember2020-09-152020-09-150001778016imab:ImabHangzhouMemberimab:ManagementHoldcoMember2020-09-152020-09-150001778016imab:ImabHangzhouMember2021-01-012021-06-300001778016imab:JumpcanAgreementMember2022-01-012022-06-300001778016us-gaap:CommonStockMember2021-01-012021-06-300001778016us-gaap:AdditionalPaidInCapitalMember2021-01-012021-06-3000017780162021-01-012021-06-3000017780162022-06-3000017780162021-12-3100017780162020-02-100001778016imab:ZhejiangTianliPharmaceuticalSalesCoLtdMember2022-01-012022-06-300001778016imab:IMabtianjinMember2022-01-012022-06-300001778016imab:IMabShanghaiMember2022-01-012022-06-300001778016imab:ImabbiopharmaUsLtdMember2022-01-012022-06-300001778016imab:IMabBiopharmaHongKongLimitedMember2022-01-012022-06-30xbrli:pureiso4217:CNYiso4217:USDxbrli:sharesiso4217:USDxbrli:sharesiso4217:CNYxbrli:sharesiso4217:USDiso4217:CNYimab:segment

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2022

--------------

Commission File Number: 001-39173

----------

I-MAB

55th – 56th Floor, New Bund Center, 555 West Haiyang Road, Pudong District

Shanghai, 200124

People’s Republic of China

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F

Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

EXPLANATORY NOTE

Exhibits 99.1, 99.2 and 99.3 to this current report on Form 6-K are incorporated by reference into the registration statement on Form F-3 of I-Mab (File No. 333-252793) and shall be a part thereof from the date on which this current report is furnished, to the extent not superseded by documents or reports subsequently filed or furnished.

EXHIBIT INDEX

Exhibit No.

Description

99.1

Unaudited Condensed Consolidated Interim Financial Statements

99.2

Discussion of Unaudited Financial Statements

99.3

Recent Developments

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

I-MAB

By       :

/s/ Richard Yeh

Name  :

Richard Yeh

Title    :

Chief Operating Officer and Interim Chief Financial Officer

Date: November 10, 2022

1688271901888573531888573536.385.540.8314.6712.741.901688271901888573531888573536.385.540.831838267531911273362.311223000001741000000

Table of Contents

Exhibit 99.1

I-Mab

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

Unaudited Interim Condensed Consolidated Financial Statements for the Six Months Ended June 30, 2021 and 2022

 

  

Page

 

Consolidated Balance Sheet as of December 31, 2021 and Unaudited Interim Condensed Consolidated Balance Sheet as of June 30, 2022

  

F-2

 

Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss for the Six Months Ended June 30, 2021 and 2022

  

F-3

 

Unaudited Interim Condensed Consolidated Statements of Changes in Shareholders’ Equity for the Six Months Ended June 30, 2021 and 2022

  

F-4

 

Unaudited Interim Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2021 and 2022

  

F-6

 

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

  

F-8

 

F-1

Table of Contents

I-MAB

Consolidated Balance Sheets as of December 31, 2021 and

Unaudited Interim Condensed Consolidated Balance Sheet as of June 30, 2022

(All amounts in thousands, except for share and per share data, unless otherwise noted)

As of December 31,

As of June 30, 

2021

2022

    

Notes

    

RMB

    

RMB

    

US$ (Note 2.5)

Assets

 

  

 

  

 

  

 

  

Current assets

 

  

 

  

 

  

 

  

Cash and cash equivalents

 

3,523,632

 

3,710,901

 

554,023

Accounts receivable

 

3, 14

 

33,081

 

510

 

76

Contract assets

 

3, 14

 

253,780

 

291,079

 

43,457

Short-term investments

 

2.4, 2.8

 

753,164

 

211,184

 

31,529

Inventories

 

4

 

27,237

 

 

Prepayments and other receivables

 

5

 

190,824

 

101,004

 

15,080

Total current assets

 

4,781,718

 

4,314,678

 

644,165

Property, equipment and software

 

6

 

45,716

 

61,141

 

9,128

Operating lease right-of-use assets

 

 

112,781

 

100,860

 

15,058

Intangible assets

 

7

 

119,666

 

119,277

 

17,808

Goodwill

 

8

 

162,574

 

162,574

 

24,272

Investments accounted for using the equity method

 

9(a)

 

352,106

 

217,662

 

32,496

Other non-current assets

 

26,634

 

15,380

 

2,296

Total assets

 

5,601,195

 

4,991,572

 

745,223

Liabilities and shareholders’ equity

 

  

 

  

 

  

 

  

Current liabilities

 

  

 

  

 

  

 

  

Accruals and other payables

 

10

 

593,335

 

547,472

 

81,736

Operating lease liabilities, current

 

 

30,669

 

42,527

 

6,349

Total current liabilities

 

624,004

 

589,999

 

88,085

Put right liabilities

 

2.4, 9(b)

 

96,911

 

70,242

 

10,487

Contract liabilities

 

14

 

224,000

 

240,006

 

35,832

Operating lease liabilities, non-current

 

 

81,786

 

61,302

 

9,152

Other non-current liabilities

 

10

 

14,934

 

13,948

 

2,082

Total liabilities

 

1,041,635

 

975,497

 

145,638

Commitments and contingencies

 

18

 

  

 

  

 

  

Shareholders’ equity

 

  

 

  

 

  

 

  

Ordinary shares (US$0.0001 par value, 800,000,000 shares authorized as of December 31, 2021 and June 30, 2022, respectively; 183,826,753 and 191,127,336 shares issued and outstanding as of December 31, 2021 and June 30, 2022, respectively)

 

11

 

126

 

131

 

20

Additional paid-in capital

 

9,100,777

 

9,370,583

 

1,398,991

Accumulated other comprehensive income (loss)

 

(186,510)

 

47,051

 

7,025

Accumulated deficit

 

(4,354,833)

 

(5,401,690)

 

(806,451)

Total shareholders’ equity

 

4,559,560

 

4,016,075

 

599,585

Total liabilities and shareholders’ equity

 

5,601,195

 

4,991,572

 

745,223

The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.

F-2

Table of Contents

I-MAB

Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss

For the Six Months Ended June 30, 2021 and 2022

(All amounts in thousands, except for share and per share data, unless otherwise noted)

Six Months Ended June 30, 

2021

2022

    

Notes

    

RMB

    

RMB

    

US$ (Note 2.5)

Revenues

 

  

 

  

 

  

 

  

Licensing and collaboration revenue

 

14

 

17,775

 

23,756

 

3,547

Supply of investigational products

 

4

 

 

28,102

 

4,195

Total revenues

 

17,775

 

51,858

 

7,742

Cost of revenues

 

 

(27,237)

 

(4,066)

Expenses

 

  

 

  

 

  

 

  

Research and development expenses

 

2.18

 

(592,993)

 

(452,618)

 

(67,574)

Administrative expenses

 

(451,500)

 

(392,460)

 

(58,593)

Loss from operations

 

(1,026,718)

 

(820,457)

 

(122,491)

Interest income

 

9,409

 

6,566

 

980

Other income (expense), net

 

15

 

51,904

 

(51,944)

 

(7,755)

Equity in loss of affiliates

 

9

 

(114,200)

 

(181,022)

 

(27,026)

Loss before income tax expense

 

(1,079,605)

 

(1,046,857)

 

(156,292)

Income tax benefit

 

 

3,124

 

 

Net loss attributable to I-MAB

 

(1,076,481)

 

(1,046,857)

 

(156,292)

Net loss attributable to ordinary shareholders

 

(1,076,481)

 

(1,046,857)

 

(156,292)

Net loss attributable to I-MAB

 

(1,076,481)

 

(1,046,857)

 

(156,292)

Other comprehensive income (loss):

 

  

 

  

 

  

 

  

Foreign currency translation adjustments, net of nil tax

 

(73,577)

 

233,561

 

34,870

Total comprehensive loss attributable to I-MAB

 

(1,150,058)

 

(813,296)

 

(121,422)

Net loss attributable to ordinary shareholders

 

(1,076,481)

 

(1,046,857)

 

(156,292)

Weighted-average number of ordinary shares used in calculating net loss per share - basic and diluted

 

16

 

168,827,190

 

188,857,353

 

188,857,353

Net loss per share attributable to ordinary shareholders

 

  

 

  

 

  

 

  

—Basic and diluted

 

16

 

(6.38)

 

(5.54)

 

(0.83)

Net loss per ADS attributable to ordinary shareholders

 

  

 

  

 

  

 

  

—Basic and diluted

 

(14.67)

 

(12.74)

 

(1.90)

The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.

F-3

Table of Contents

I-MAB

Unaudited Interim Condensed Consolidated Statements of Changes in Shareholders’ Equity

For the Six Months Ended June 30, 2021 and 2022

(All amounts in thousands, except for share and per share data, unless otherwise noted)

Ordinary share

Accumulated

(Note 11)

other

(US$0.0001 par value)

Additional

comprehensive

Total

Number of

paid-in

income

Accumulated

shareholders’

shares

Amount

capital

 

(loss)

deficit

equity

    

    

RMB

    

RMB

    

RMB

    

RMB

    

RMB

Balance as of December 31, 2020

 

164,888,519

 

114

 

7,701,116

 

(50,793)

 

(2,023,292)

 

5,627,145

Foreign currency translation adjustments

 

 

 

 

(73,577)

 

 

(73,577)

Net loss

 

 

 

 

 

(1,076,481)

 

(1,076,481)

Share-based compensation of I-Mab

 

 

 

334,723

 

 

 

334,723

Exercise of stock options

 

3,735,578

 

3

 

24,217

 

 

 

24,220

Issuance of ordinary shares for restricted share units (Note 13(d))

 

3,706,767

 

2

 

3,112

 

 

 

3,114

Exercise of warrants (Note 12)

4,683,191

3

589,390

589,393

Proportionate share of share-based compensation expenses recorded in an equity method affiliate (Note 9 (a))

 

 

 

31,158

 

 

 

31,158

Balance as of June 30, 2021

 

177,014,055

 

122

 

8,683,716

 

(124,370)

 

(3,099,773)

 

5,459,695

F-4

Table of Contents

I-MAB

Unaudited Interim Condensed Consolidated Statements of Changes in Shareholders’ Equity (Continued)

For the Six Months Ended June 30, 2021 and 2022

(All amounts in thousands, except for share and per share data, unless otherwise noted)

Ordinary share

(Note 11)

Accumulated

(US$0.0001 par value)

Additional

other

Total

Number of

paid-in

comprehensive

Accumulated

shareholders’

shares

Amount

capital

 

loss

deficit

equity

    

    

RMB

    

RMB

    

RMB

    

RMB

    

RMB

Balance as of December 31, 2021

 

183,826,753

 

126

 

9,100,777

 

(186,510)

 

(4,354,833)

 

4,559,560

Foreign currency translation adjustments

 

 

 

 

233,561

 

 

233,561

Net loss

 

 

 

 

 

(1,046,857)

 

(1,046,857)

Share-based compensation of I-Mab

 

 

 

196,942

 

 

 

196,942

Exercise of stock options

 

6,213,789

 

4

 

40,167

 

 

 

40,171

Issuance of ordinary shares for restricted share units (Note 13)

 

1,086,794

 

1

 

(1)

 

 

 

Proportionate share of share-based compensation expenses recorded in an equity method affiliate (Note 9(a))

 

 

 

32,698

 

 

 

32,698

Balance as of June 30, 2022

 

191,127,336

 

131

 

9,370,583

 

47,051

 

(5,401,690)

 

4,016,075

F-5

Table of Contents

I-MAB

Unaudited Interim Condensed Consolidated Statements of Cash Flows

For the Six Months Ended June 30, 2021 and 2022

(All amounts in thousands, except for share and per share data, unless otherwise noted)

Six Months Ended June 30, 

2021

2022

    

RMB

    

RMB

    

US$ (Note 2.5)

Cash flows from operating activities

 

  

 

  

 

  

Net loss

 

(1,076,481)

 

(1,046,857)

 

(156,292)

Adjustments to reconcile net loss to net cash used in operating activities

 

  

 

  

 

  

Depreciation of property, equipment and software

 

6,729

 

12,201

 

1,822

Amortization of intangible assets

 

389

 

389

 

58

Loss on disposal of property, equipment and software

 

279

 

7

 

1

Gain on disposal of right-of-use assets

 

 

(56)

 

(8)

Fair value change of put right liabilities

 

(14,618)

 

(30,798)

 

(4,598)

Equity in loss of affiliates

 

114,200

 

181,022

 

27,026

Share-based compensation

 

334,723

 

196,942

 

29,403

Amortization of right-of use assets and interest of lease liabilities

 

6,817

 

21,072

 

3,146

Recognition of deferred cost for planned dual listing

14,613

2,182

Fair value change of short-term and other investments

 

(13,494)

 

23,765

 

3,548

Changes in operating assets and liabilities

 

  

 

  

 

  

Accounts receivable

 

130,498

 

32,571

 

4,863

Contract assets

 

(15,514)

 

(37,299)

 

(5,569)

Prepayments and other receivables

 

(8,115)

 

85,464

 

12,758

Inventories

 

 

27,237

 

4,066

Accruals and other payables

 

104,486

 

(49,090)

 

(7,329)

Contract liabilities

 

 

16,006

 

2,390

Other non-current liabilities

 

(2,775)

 

(986)

 

(147)

Deferred subsidy income

 

(2,949)

 

 

Lease liabilities

 

(6,817)

 

(17,361)

 

(2,592)

Net cash used in operating activities

 

(442,642)

 

(571,158)

 

(85,272)

Cash flows from investing activities

 

  

 

  

 

  

Purchase of property, equipment and software

 

(4,061)

 

(18,875)

 

(2,818)

Proceeds from disposal of short-term and other investments

 

3,676,642

 

2,326,215

 

347,295

Purchase of short-term and other investments

 

(4,053,963)

 

(1,808,000)

 

(269,927)

Net cash generated from (used in) investing activities

 

(381,382)

 

499,340

 

74,550

F-6

Table of Contents

I-MAB

Unaudited Interim Condensed Consolidated Statements of Cash Flows (Continued)

For the Six Months Ended June 30, 2021 and 2022

(All amounts in thousands, except for share and per share data, unless otherwise noted)

Six Months Ended June 30, 

2021

2022

    

RMB

    

RMB

    

US$ (Note 2.5)

Cash flows from financing activities

 

  

 

  

 

  

Payments of the issuance cost in relation to private placement

 

(128,786)

 

 

Payments of cost in relation to planned dual listing

 

(1,698)

 

(4,793)

 

(715)

Proceeds from exercise of warrants

 

589,393

 

 

Proceeds from exercise of stock options

 

24,220

 

40,171

 

5,997

Proceeds from issuance of ordinary shares for restricted share units

 

3,114

 

 

Net cash generated from financing activities

 

486,243

 

35,378

 

5,282

Effect of exchange rate changes on cash and cash equivalents

 

(70,942)

 

223,709

 

33,399

Net increase (decrease) in cash and cash equivalents

 

(408,723)

 

187,269

 

27,959

Cash and cash equivalents, beginning of the period

 

4,758,778

 

3,523,632

 

526,064

Cash and cash equivalents, end of the period

 

4,350,055

 

3,710,901

 

554,023

Additional ASC 842 supplemental disclosures

Cash paid for fixed operating lease costs included in the measurement of lease obligations in operating activities

6,817

17,361

2,592

Right-of-use assets obtained in exchange for operating lease obligations

34,057

6,851

1,023

Other supplemental cash flow disclosures

Withholding income tax paid

9,077

Non-cash activities

Accrued planned dual listing costs payable

1,916

Payables for purchase of property, equipment and software

14,699

2,195

The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.

F-7

Table of Contents

I-MAB

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

(All amounts in thousands, except for share and per share data, unless otherwise noted)

1. PRINCIPAL ACTIVITIES AND ORGANIZATION

I-Mab (the “Company”) was incorporated in the Cayman Islands on June 30, 2016 as an exempted company with limited liability under the Companies Act of the Cayman Islands. The Company and its subsidiaries (together the “Group”) are principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People’s Republic of China (the “PRC”) and other countries and regions.

As of June 30, 2022, the Company’s principal subsidiaries are as follows:

    

Percentage

of direct

or indirect

Date of

ownership

Place of

incorporation or

by the

Subsidiaries

    

incorporation

    

acquisition

    

Company

    

Principal activities

I-Mab Biopharma Hong Kong Limited (“I-Mab Hong Kong”)

 

Hong Kong

July 8, 2016

 

100

%  

Investment holding

I-Mab Biopharma Co., Ltd. (“I-Mab Shanghai”)

 

PRC

August 24, 2016

 

100

%  

Research and development of innovative medicines

I-Mab Bio-tech (Tianjin) Co., Ltd. (“I-Mab Tianjin”)

 

PRC

July 15, 2017

 

100

%  

Research and development of innovative medicines

I-Mab Biopharma US Ltd.

 

U.S.

February 28, 2018

 

100

%  

Research and development of innovative medicines

Zhejiang Tianli Pharmaceutical Sales Co., Ltd.

 

PRC

September 29,2021

 

100

%  

Sales and distribution of medicine products

F-8

Table of Contents

I-MAB

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

(All amounts in thousands, except for share and per share data, unless otherwise noted)

2. PRINCIPAL ACCOUNTING POLICIES

2.1 Basis of presentation

The accompanying unaudited interim condensed consolidated financial statements of the Group have been prepared in accordance with the accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information. Accordingly, they do not include all of the information and footnotes normally included in the annual financial statements prepared in accordance with U.S. GAAP. Certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted consistent with Article 10 of Regulation S-X. In the opinion of management, the Group’s unaudited interim condensed consolidated financial statements and accompanying notes include all adjustments (consisting of normal recurring adjustments) considered necessary for the fair statement of the Group’s financial position as of June 30, 2022, and results of operations and cash flows for the six months ended June 30, 2021 and 2022. Interim results of operations are not necessarily indicative of the results for the full year or for any future period. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements as of and for the year ended December 31, 2021, and related notes included in the Group’s audited consolidated financial statements. The financial information as of June 30, 2022 presented in the unaudited interim condensed consolidated financial statements is derived from the audited consolidated financial statements as of December 31, 2021.

Significant accounting policies followed by the Group in the preparation of the accompanying consolidated financial statements are summarized below.

2.2 Basis of consolidation

The accompanying consolidated financial statements reflect the accounts of the Company and all of its subsidiaries in which a controlling interest is maintained. All inter-company balances and transactions have been eliminated in consolidation.

The Group consolidates entities in which it has a controlling financial interest based on either the variable interest entity (VIE) or voting interest model. The Group is required to first apply the VIE model to determine whether it holds a variable interest in an entity, and if so, whether the entity is a VIE. If the Group determines it does not hold a variable interest in a VIE, it then applies the voting interest model. Under the voting interest model, the Group consolidates an entity when it holds a majority voting interest in an entity.

The Company accounts for investments in which it has significant influence but not a controlling financial interest using the equity method of accounting (see Note 9).

VIE Model

An entity is considered to be a VIE if any of the following conditions exist: (a) the total equity investment at risk is not sufficient to permit the entity to finance its activities without additional subordinated financial support, (b) the holders of the equity investment at risk, as a group, lack either the direct or indirect ability through voting rights or similar rights to make decisions that have a significant effect on the success of the entity or the obligation to absorb the entity’s expected losses or right to receive the entity’s expected residual returns, or (c) the voting rights of some equity investors are disproportionate to their obligation to absorb losses of the entity, their rights to receive returns from an entity, or both and substantially all of the entity’s activities either involve or are conducted on behalf of an investor with disproportionately few voting rights.

Under the VIE model, limited partnerships are considered VIE unless the limited partners hold substantive kick-out or participating rights over the general partner. The Group consolidates entities that are VIEs when the Group determines it is the primary beneficiary. Generally, the primary beneficiary of a VIE is a reporting entity that has (a) the power to direct the activities that most significantly affect the VIE’s economic performance, and (b) the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE.

As of December 31, 2021 and June 30, 2022, the Group determined that the one entity subject to the consolidation guidance is a VIE for which the Group is not the primary beneficiary.

F-9

Table of Contents

I-MAB

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

(All amounts in thousands, except for share and per share data, unless otherwise noted)

2. PRINCIPAL ACCOUNTING POLICIES (CONTINUED)

2.3 Use of estimates

The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates are used when accounting for amounts recorded in connection with acquisitions, including initial fair value determinations of assets and liabilities and other intangible assets as well as subsequent fair value measurements. Additionally, estimates are used in determining items such as fair value measurements of short-term investments and put right liabilities, impairment of accounts receivables, contract assets, other receivables, long-lived assets, intangible assets and goodwill, useful lives of property, equipment and software, recognition of right-of-use assets and lease liabilities, cost-to-cost measure of progress for over time performance obligations, valuation of share-based compensation arrangements, deferred tax assets valuation allowances and provision for ongoing litigation. Management bases the estimates on historical experience, known trends and various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates.

2.4 Fair value measurements

Financial assets and liabilities of the Group primarily comprise of cash and cash equivalents, short-term investments, accounts receivable, contract assets, other receivables, short-term borrowings, accruals and other payables and put right liabilities. As of December 31, 2021 and June 30, 2022, except for short-term investments and put right liabilities, the carrying values of these financial assets and liabilities approximated their fair values because of their generally short maturities. The Group reports short-term investments and put right liabilities at fair value at each balance sheet date and changes in fair value are reflected in the consolidated statements of comprehensive loss.

The Group measures its financial assets and liabilities using inputs from the following three levels of the fair value hierarchy. The three levels are as follows:

Level 1 inputs are unadjusted quoted prices in active markets for identical assets that the management has the ability to access at the measurement date.

Level 2 inputs include quoted prices for similar assets in active markets, quoted prices for identical or similar assets in markets that are not active, inputs other than quoted prices that are observable for the asset (i.e., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).

Level 3 includes unobservable inputs that reflect the management’s assumptions about the assumptions that market participants would use in pricing the asset. The management develops these inputs based on the best information available, including the own data.

F-10

Table of Contents

I-MAB

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

(All amounts in thousands, except for share and per share data, unless otherwise noted)

2. PRINCIPAL ACCOUNTING POLICIES (CONTINUED)

2.4 Fair value measurements (continued)

Assets and liabilities measured at fair value on a recurring basis

The Group measures its short-term investments and put right liabilities at fair value on a recurring basis. As the Group’s short-term investments and put right liabilities are not traded in an active market with readily observable prices, the Group uses significant unobservable inputs to measure the fair value of short-term investments and put right liabilities. These instruments are categorized in the Level 3 valuation hierarchy based on the significance of unobservable factors in the overall fair value measurement.

The following table summarizes the Group’s financial assets and liabilities measured and recorded at fair value on a recurring basis as of December 31, 2021 and June 30, 2022:

    

As of December 31, 2021

Non-

Active market

Observable input

 observable input

    

(Level 1)

    

(Level 2)

    

(Level 3)

    

Total

RMB

RMB

RMB

RMB

Assets:

  

  

  

  

Short-term investments

 

 

 

753,164

 

753,164

Liabilities:

 

  

 

  

 

  

 

  

Put right liabilities

 

 

 

96,911

 

96,911

    

As of June 30, 2022

Non- 

Active market 

Observable input

observable input 

    

(Level 1)

    

 (Level 2)

    

(Level 3)

    

Total

RMB

RMB

RMB

RMB

Assets:

  

  

  

  

Short-term investments

211,184

211,184

Liabilities:

 

  

 

  

 

  

 

  

Put right liabilities

 

 

 

70,242

 

70,242

The roll forward of major Level 3 financial assets and financial liabilities are as follows:

    

Short-term

    

Put right

and other investments

 liabilities

RMB

RMB

Fair value of Level 3 financial assets and liabilities as of December 31, 2021

 

753,164

 

96,911

Purchase of short-term and other investments

 

1,808,000

 

Disposal of short-term and other investments

 

(2,326,215)

 

Fair value changes

 

(23,765)

 

(30,798)

Currency translation differences

 

 

4,129

Fair value of Level 3 financial assets and liabilities as of June 30, 2022

 

211,184

 

70,242

See Note 9(b) for additional information about Level 3 put right liabilities measured at fair value on a recurring basis for as of December 31, 2021 and June 30, 2022.

F-11

Table of Contents

I-MAB

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

(All amounts in thousands, except for share and per share data, unless otherwise noted)

2. PRINCIPAL ACCOUNTING POLICIES (CONTINUED)

2.5 Foreign currency translation

The Group uses Chinese Renminbi (“RMB”) as its reporting currency. The United States Dollar (“US$”) is the functional currency of the Group’s entities incorporated in the Cayman Islands, the United States of America (“U.S.”) and Hong Kong and the RMB is the functional currency of the Company’s PRC subsidiaries.

Transactions denominated in other than the functional currencies are translated into the functional currency of the entity at the exchange rates prevailing on the transaction dates. Assets and liabilities denominated in other than the functional currencies are translated at the balance sheet date exchange rate. The resulting exchange differences are recorded in the consolidated statements of comprehensive loss.

The consolidated financial statements of the Group are translated from the functional currency to the reporting currency, RMB. Assets and liabilities of the subsidiaries are translated into RMB using the exchange rate in effect at each balance sheet date. Income and expenses are translated at the average exchange rates prevailing for the year. Foreign currency translation adjustments arising from these are reflected in the accumulated other comprehensive loss. The exchange rates used for translation on December 31, 2021 and June 30, 2022 were US$1.00 = RMB6.3757 and RMB6.7114 respectively, representing the index rates stipulated by the People’s Bank of China.

Translations of balances in the consolidated balance sheets, consolidated statements of comprehensive loss, consolidated statements of changes in shareholders’ equity and consolidated statements of cash flows from RMB into US$ as of and for the six months ended June 30, 2022 are solely for the convenience of the readers and were calculated at the rate of US$1.00=RMB6.6981, representing the noon buying rate in The City of New York for cable transfers of RMB as certified for customs purposes by the Federal Reserve Bank of New York on June 30, 2022. No representation is made that the RMB amounts could have been, or could be, converted, realized or settled into US$ at that rate on June 30, 2021, or at any other rate. The US$ convenience translation is not required under U.S. GAAP and all US$ convenience translation amounts in the accompanying consolidated financial statements are unaudited.

2.6 Cash and cash equivalents

Cash and cash equivalents consist of cash on hand and bank deposits, which are unrestricted as to withdrawal and use. The Group considers all highly liquid investments with an original maturity date of three months or less at the date of purchase to be cash equivalents.

2.7 Accounts receivable

Accounts receivable are stated at amortized cost less allowance for credit losses. The allowance for credit losses reflects the best estimate of future losses over the contractual life of outstanding accounts receivable and is determined on the basis of historical experience, specific allowances for known troubled accounts, other currently available information including customer financial condition, and both current and forecasted economic conditions.

2.8 Short-term investments

Short-term investments represent the investments issued by commercial banks or other financial institutions with a variable interest rate indexed to the performance of underlying assets within one year. These investments are stated at fair value. Changes in the fair value are reflected in the consolidated statements of comprehensive loss.

F-12

Table of Contents

I-MAB

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

(All amounts in thousands, except for share and per share data, unless otherwise noted)

2. PRINCIPAL ACCOUNTING POLICIES (CONTINUED)

2.9 Inventories

Prior to the regulatory approval of product candidates, the Company may incur expenses for the manufacture of drug product to support the commercial launch of those products. Until the date at which regulatory approval has been received or is otherwise considered probable, all such costs are recorded as research and development expenses as incurred.

Investigational products for external supply are capitalized as inventories with probable future economic benefit. Inventories are stated at the lower of cost and net realizable value, with cost determined in a manner that approximates the first-in, first-out method. The Company periodically analyzes its inventory levels, and writes down inventory that has become obsolete, inventory that has a cost basis in excess of its estimated realizable value and inventory in excess of expected sales requirements as cost of product sales. The determination of whether inventory costs will be realizable requires estimates by management. If actual market conditions are less favorable than projected by management, additional write-downs of inventory may be required, which would be recorded in the consolidated statements of comprehensive loss.

2.10 Property, equipment and software

Property, equipment and software are stated at cost less accumulated depreciation and amortization. Depreciation and amortization is computed using the straight-line method over the following estimated useful lives, taking into account of any estimated residual value:

Laboratory equipment

    

3 to 10 years

Software

1 to 5 years

Office furniture and equipment

5 years

Delivery equipment

4 years

Leasehold improvements

Lesser of useful life or lease term

The Group recognizes the gain or loss on the disposal of property, equipment and software in the consolidated statements of comprehensive loss.

2.11 Intangible assets

Intangible assets acquired in a business combination that are used in research and development activities, or in-process research and development (IPR&D) intangible assets, are considered indefinite lived until the completion or abandonment of the associated research and development efforts. During the period that those assets are considered indefinite lived, they are not amortized but are tested for impairment annually and more frequently if events or changes in circumstances indicate that it is more likely than not that the asset is impaired. If after assessing the totality of events and circumstances and their potential effect on significant inputs to the fair value determination the Group determines that it is not more likely than not that the indefinite-lived intangible is impaired, then the entity shall calculate the fair value of the intangible asset and perform the quantitative impairment test by comparing the fair value of the asset with its carrying amount. If the carrying amount exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. For IPR&D assets, the impairment loss is recognized in research and development expenses in the consolidated statements of comprehensive loss.

F-13

Table of Contents

I-MAB

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

(All amounts in thousands, except for share and per share data, unless otherwise noted)

2. PRINCIPAL ACCOUNTING POLICIES (CONTINUED)

2.11 Intangible assets (continued)

Intangible assets with finite useful lives are amortized over their useful lives. The useful life of an intangible asset is the period over which the asset is expected to contribute directly or indirectly to the future cash flows of the Group. The Group uses the straight-line amortization method when the economic benefits of the intangible assets are consumed or otherwise used up cannot be reliably determined. In particular, the Group amortizes the contract related intangible assets with finite useful lives over 10 to 20 years on a straight-line basis in accordance with the economic life of the out-licensed patent. Intangible assets subject to amortization are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an intangible asset may not be recoverable. If circumstances require an intangible asset be tested for possible impairment, the Group first compares undiscounted cash flows expected to be generated by that asset to its carrying amount. If the carrying amount is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying amount exceeds its fair value. For intangible assets with finite useful life, the impairment loss is recognized in cost of revenues in the consolidated statements of comprehensive loss.

2.12 Impairment of long-lived assets

Long-lived assets, such as property, plant, and software, and intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying amount. If the carrying amount of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying amount exceeds its fair value. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary. As of December 31, 2021 and June 30, 2022, there was no impairment of the value of the Group’s long-lived assets.

2.13 Goodwill

Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. The Group allocates the cost of an acquired entity to the assets acquired and liabilities assumed based on their estimated fair values at the date of acquisition. The excess of the purchase price for acquisitions over the fair value of the net assets acquired, including other intangible assets, is recorded as goodwill. Goodwill is not amortized, but impairment of goodwill is tested on at least an annual basis or whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable.

The Group first assesses qualitative factors to determine whether it is more likely than not that the fair value of the Group’s reporting unit is less than its carrying amount, including goodwill. The qualitative assessment includes the Group’s evaluation of relevant events and circumstances affecting the Group’s single reporting unit, including macroeconomic, industry, market conditions and the Group’s overall financial performance. If qualitative factors indicate that it is more likely than not that the Group’s reporting unit’s fair value is less than its carrying amount, then the Group will perform the quantitative impairment test by comparing the reporting unit’s carrying amount, including goodwill, to its fair value. If the carrying amount of the reporting unit exceeds its fair value, an impairment loss will be recognized in an amount equal to that excess. As of December 31, 2021 and June 30, 2022, the Group determined that there were no indicators of impairment of the goodwill.

F-14

Table of Contents

I-MAB

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

(All amounts in thousands, except for share and per share data, unless otherwise noted)

2. PRINCIPAL ACCOUNTING POLICIES (CONTINUED)

2.14 Long-term investments

The Group’s long-term investments include equity investments in an affiliate in which it does not have a controlling financial interest, but has the ability to exercise significant influence over the operating and financial policies of the investee. The investment is accounted for using the equity method of accounting in accordance with ASC topic 323, Investments—Equity Method and Joint Ventures (“ASC 323”). Under the equity method, the Group initially records its investments at fair value. The Group subsequently adjusts the carrying amount of the investment to recognize the Group’s proportionate share of the equity investee’s net income or loss after the date of investment. When the liquidation rights and priorities as defined by an equity investment agreement differ from what is reflected by the underlying percentage ownership interests, applying the percentage ownership interest to U.S. GAAP net income in order to determine earnings or losses does not accurately represent the income allocation and cash flow distributions that will ultimately be received by the investors. As such, for this type of investments, the Group uses the Hypothetical Liquidation at Book Value (“HLBV”) method for allocating earnings or losses of the equity method investee. The HLBV method is considered as a balance sheet approach. Specifically, a calculation is prepared at each balance sheet date to determine the amount that the Group would receive if an equity investment entity were to liquidate all of its assets (as valued in accordance with U.S. GAAP) and distribute that cash to the investors based on the contractually defined liquidation priorities. The difference between the calculated liquidation distribution amounts at the beginning and the end of the reporting period, after adjusting for capital contributions and distributions, is the Group’s share of the earnings or losses from the equity investment for the period.

As it relates to the share-based compensation awarded by an equity method investee to its own employees, the Group recognizes its proportionate share of the compensation expense over the vesting period, included in the equity in loss of affiliate in the consolidated statements of comprehensive loss. As it relates to the share-based compensation awarded by the Group to the equity method investee employees that are based on the Group’s stock, when the other investors do not provide proportionate value to the investee or the Group does not receive any consideration, the Group expenses the entire cost associated with the award in the same period the costs are recognized by the investee, to the extent that the Group’s claim on the investee’s book value has not been increased. The expenses recognized by the Group is included in the equity in loss of affiliate in the consolidated statements of comprehensive loss.

The Group evaluates the equity method investment for impairment under ASC 323. An impairment loss on the equity method investments is recognized in losses when the decline in value is determined to be other-than-temporary. No impairment charge was recognized for the year ended December 31, 2021 and six months ended June 30, 2022.

2.15 Deferred subsidy income

Deferred subsidy income consists of deferred income from government grants. Government grants mainly consist of cash subsidies received by the Group’s subsidiaries in the PRC from local governments as support on expenses relating to certain projects. Grants received with government specified performance obligations are recognized as other income when all the obligations have been satisfied. If such obligations are not satisfied, the Group may be required to refund the subsidy.

2.16 Revenue recognition

The Group adopted Accounting Standard Codification (“ASC”) 606, Revenue from Contracts with Customers (Topic 606) (“ASC 606”) for all periods presented. Consistent with the criteria of Topic 606, the Group recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to receive in exchange for those goods or services.

Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. An the entity performs the following five steps to account for the arrangements that an entity determines are within the scope of ASC 606: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.

F-15

Table of Contents

I-MAB

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

(All amounts in thousands, except for share and per share data, unless otherwise noted)

2. PRINCIPAL ACCOUNTING POLICIES (CONTINUED)

2.16 Revenue recognition (continued)

Once a contract is determined to be within the scope of ASC 606 at contract inception, the Group audits the contract to determine which performance obligations it must deliver and which of these performance obligations are distinct. The Group recognizes as revenue the amount of the transaction price that is allocated to each performance obligation when that performance obligation is satisfied or as it is satisfied.

Collaboration revenue

At contract inception, we analyze its collaboration arrangements to assess whether they are within the scope of ASC 808, Collaborative Arrangements (“ASC 808”) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, we first determine if the collaboration is deemed to be within the scope of ASC 808. For any units of account that are reflective of a vendor-customer relationship those units of account are accounted for within the scope of ASC 606. For any units of account that are not accounted for under ASC 606 and therefore accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently.

The Group’s collaborative arrangements may contain more than one unit of account, or performance obligation, such as grant of licenses of intellectual property rights, promises to provide research and development services and other deliverables. The collaborative arrangements do not include a right of return for any deliverable. When multiple units of account or performance obligations are identified within the arrangements, the Group must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. In developing the stand-alone selling price for a performance obligation, the Group considers competitor pricing for a similar or identical product, market awareness of and perception of the product, expected product life and current market trends. In general, the consideration allocated to each performance obligation is recognized when the respective obligation is satisfied either by delivering a good or providing a service, limited to the consideration that is not constrained.

Licenses of Intellectual Property:Upfront non-refundable payments for licensing the Group’s intellectual property are evaluated to determine if the license is distinct from the other performance obligations identified in the arrangement. For the license that is determined to be distinct, the Group recognizes revenues in the amount of non-refundable, up-front fees allocated to the license at a point in time, upon which the license is transferred to the licensee and the licensee is able to use and benefit from the license.

Research and Development Services: The portion of the transaction price allocated to research and development services performance obligations is deferred and recognized as revenue over time as delivery or performance of such services provided to the Group’s customers occurs.

Milestone Payments: At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, the Group evaluates whether the milestones are considered probable of being reached and to the extent that a significant reversal of cumulative revenue would not occur in future periods, estimates the amount to be included in the transaction price using the most likely amount method. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Group recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Group re-evaluates the probability of achieving such development milestones and any related constraint, and if necessary, adjust the estimate of the overall transaction price. Any resulting adjustment is recorded on a cumulative catch-up basis, which would affect the Group’s reported revenues and earnings in the period of the adjustment.

Royalties: For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the sales-based royalties or milestone payments relate, the Group recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).

F-16

Table of Contents

I-MAB

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

(All amounts in thousands, except for share and per share data, unless otherwise noted)

2. PRINCIPAL ACCOUNTING POLICIES (CONTINUED)

2.16 Revenue recognition (continued)

Supply of investigational products

Revenue from supply of investigational products is recognized when there is a transfer of control from the Group to the customer. The Group determines transfer of control based on when the product is delivered, and title passed to the customer. Sales are generally made with a limited right of return under certain conditions. Revenues are recorded net of provisions for sales discounts and returns.

Contract assets and liabilities

Contract assets primarily represent revenue earnings over time that are not yet billable based on the terms of the contracts. The Group does not have impairment losses associated with contracts with customers for the year ended December 31, 2021 and six months ended June 30, 2022.

Contract liabilities consist of fees invoiced or paid by the Group’s customers for which the associated performance obligations have not been satisfied and revenue has not been recognized based on the Group’s revenue recognition criteria described above.

Contract assets and contract liabilities are reported in a net position on an individual contract basis at the end of each reporting period. Contract assets are classified as current in the consolidated balance sheet when the Group expects to complete the related performance obligations and invoice the customers within one year of the balance sheet date, and as long-term when the Group expects to complete the related performance obligations and invoice the customers more than one year out from the balance sheet date. Contract liabilities are classified as current in the consolidated balance sheet when the revenue recognition associated with the related customer payments and invoicing is expected to occur within one year of the balance sheet date and as long-term when the revenue recognition associated with the related customer payments and invoicing is expected to occur in more than one year from the balance sheet date.

Cost-to-cost measure of progress for over time performance obligations

Under the Group’s certain licensing and collaboration arrangement entered into with a business partner, the Group recognized revenue using the cost-to-cost measure of progress for its over time performance obligations as this recognition best depicts the transfer of benefits to its business partner as costs are incurred under the licensing and collaboration arrangement. Under the cost-to-cost measure of progress method, the extent of progress towards completion is measured based on the ratio of costs incurred to-date to the total estimated costs for completion of the performance obligations. The Group applied significant judgment in estimating the total estimated costs for completion of performance obligations under such licensing and collaboration arrangement.

2.17 Value-added-tax (“VAT”) recoverable and surcharges

Value added tax recoverable represent amounts paid by the Group for purchases. The surcharges (i.e., Urban construction and maintenance tax, educational surtax, local educational surtax), vary from 6% to 12% of the value-added-tax depending on the tax-payer’s location. The deductible input VAT balance is included in the prepayments and other receivables in the consolidated balance sheets, and VAT payable balance is recorded in the accruals and other payables in the consolidated balance sheets.

F-17

Table of Contents

I-MAB

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

(All amounts in thousands, except for share and per share data, unless otherwise noted)

2. PRINCIPAL ACCOUNTING POLICIES (CONTINUED)

2.18 Research and development expenses

Elements of research and development expenses primarily include (1) payroll and other related expenses of personnel engaged in research and development activities, (2) in-licensed patent rights fee of exclusive development rights of drugs granted to the Group, (3) expenses related to preclinical testing of the Group’s technologies under development and clinical trials such as payments to contract research organizations (“CRO”), investigators and clinical trial sites that conduct the clinical studies, (4) expenses to develop the product candidates, including raw materials and supplies, product testing, depreciation, and facility related expenses, and (5) other research and development expenses. Research and development expenses are charged to expenses as incurred when these expenditures are used for the Group’s research and development activities and have no alternative future uses.

The Group applied significant judgment in estimating the progress of its research and development activities and completion of or likelihood of achieving milestone events per underlying agreements when estimating the research and development costs to be accrued at each reporting period end. The process of estimating its research and development expenses involves reviewing open contracts and purchase orders, communicating with personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated costs incurred for the services when the Group has not yet been invoiced or otherwise notified of the actual costs.

The Group has acquired rights to develop and commercialize product candidates. Upfront payments that relate to the acquisition of a new drug compound, as well as pre-commercial milestone payments, are immediately expensed as acquired in-process research and development in the period in which they are incurred, provided that the new drug compound does not also include processes or activities that would constitute a “business” as defined under U.S. GAAP, the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no established alternative future use. Milestone payments made to third parties subsequent to regulatory approval are capitalized as intangible assets and amortized over the estimated remaining useful life of the related product. All development expenditures are recognized in profit or loss when incurred, as long as the conditions enabling capitalization of development expenses as an asset have not yet been met.

2.19 Leases

In accordance with ASC 842 adopted on January 1, 2019, the Group determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, operating lease liability, and operating lease liability, non-current in the Group’s consolidated balance sheets. The Group does not have any finance leases since the adoption date.

ROU assets represent the Group’s right to use an underlying asset for the lease term and lease liabilities represent the Group’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. When determining the lease term, the Group includes options to extend or terminate the lease when it is reasonably certain that it will exercise that option, if any. As the Group’s leases do not provide an implicit rate, the Group uses its incremental borrowing rate, which it calculates based on the credit quality of the Group and by comparing interest rates available in the market for similar borrowings, and adjusting this amount based on the impact of collateral over the term of each lease.

The Group has elected to adopt the following lease policies in conjunction with the adoption of ASU 2016-02: (i)elect for each lease not to separate non-lease components from lease components and instead to account for each separate lease component and the non-lease components associated with that lease component as a single lease component; (ii) for leases that have lease terms of 12 months or less and does not include a purchase option that is reasonably certain to exercise, the Group elected not to apply ASC 842 recognition requirements; and (iii) the Group elected to apply the package of practical expedients for existing arrangements entered into prior to January 1, 2019 to not reassess (a) whether an arrangement is or contains a lease, (b) the lease classification applied to existing leases, and (c) initial direct costs.

F-18

Table of Contents

I-MAB

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

(All amounts in thousands, except for share and per share data, unless otherwise noted)

2. PRINCIPAL ACCOUNTING POLICIES (CONTINUED)

2.20 Comprehensive loss

Comprehensive loss is defined as the changes in equity of the Group during a period from transactions and other events and circumstances excluding transactions resulting from investments by owners and distributions to owners. Among other disclosures, ASC 220, Comprehensive Income, requires that all items that are required to be recognized under current accounting standards as components of comprehensive loss be reported in a financial statement that is displayed with the same prominence as other financial statements. For each of the periods presented, the Group’s comprehensive loss includes net loss and foreign currency translation adjustments, which are presented in the consolidated statements of comprehensive loss.

2.21 Share-based compensation

The Group grants restricted shares and stock options to eligible employees and accounts for share-based compensation in accordance with ASC 718, Compensation—Stock Compensation.

Employees’ share-based compensation awards, if equity-classified, are measured at the grant date fair value of the awards and are recognized as expenses over the requisite period of the award, which is generally the vesting term of share-based payment awards.

A change in any of the terms or conditions of share-based awards is accounted for as a modification of the awards. The Group calculates incremental compensation expense of a modification as the excess of the fair value of the modified awards over the fair value of the original awards immediately before its terms are modified at the modification date. For vested awards, the Group recognizes incremental compensation cost in the period when the modification occurs. For awards not being fully vested, the Group recognizes the sum of the incremental compensation expense and the remaining unrecognized compensation expense for the original awards over the remaining requisite service period after modification.

Share-based compensation in relation to the restricted shares is measured based on the fair market value of the Group’s ordinary shares at the grant date of the award. Prior to the listing, estimation of the fair value of the Group’s ordinary shares involves significant assumptions that might not be observable in the market, and a number of complex and subjective variables, including discount rate, and subjective judgments regarding the Group’s projected financial and operating results, its unique business risks, the liquidity of its ordinary shares and its operating history and prospects at the time the grants are made. Share-based compensation in relation to the share options is estimated using the Binominal Option Pricing Model. The determination of the fair value of share options is affected by the share price of the Group’s ordinary shares as well as the assumptions regarding a number of complex and subjective variables, including the expected share price volatility, risk-free interest rate, exercise multiple and expected dividend yield. In addition, the forfeiture rate is estimated based on an analysis of the Group’s actual forfeitures and the appropriateness of the forfeiture rate will continue to be evaluated based on the actual forfeiture experience, analysis of employee turnover and other factors. The fair value of these awards was determined with the assistance from an independent third-party valuation firm.

F-19

Table of Contents

I-MAB

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

(All amounts in thousands, except for share and per share data, unless otherwise noted)

2. PRINCIPAL ACCOUNTING POLICIES (CONTINUED)

2.22 Income taxes

The Group accounts for income taxes under the asset and liability method. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using the enacted tax rates that expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recorded if it is more likely than not that some portion or all of the deferred income tax assets will not be utilized in the foreseeable future.

The Group evaluates its uncertain tax positions using the provisions of ASC 740-10, Income Taxes, which prescribes a recognition threshold that a tax position is required to meet before being recognized in the financial statements. The Group recognizes in the financial statements the benefit of a tax position which is ‘‘more likely than not’’ to be sustained under examination based solely on the technical merits of the position assuming a review by tax authorities having all relevant information. Tax positions that meet the recognition threshold are measured using a cumulative probability approach, at the largest amount of tax benefit that has a greater than fifty percent likelihood of being realized upon settlement. It is the Group’s policy to recognize interest and penalties related to unrecognized tax benefits, if any, as a component of income tax expense.

2.23 Business combination

The Group accounts for its business combinations using the acquisition method of accounting in accordance with ASC topic 805, Business Combinations (“ASC 805”). The acquisition method of accounting requires all of the following steps: (i) identifying the acquirer, (ii) determining the acquisition date, (iii) recognizing and measuring the identifiable assets acquired, the liabilities assumed, and any noncontrolling interest in the acquiree, and (iv) recognizing and measuring goodwill or a gain from a bargain purchase. The consideration transferred in a business combination is measured as the aggregate of the fair values at the date of exchange of the assets given, liabilities incurred, and equity instruments issued as well as the contingent considerations and all contractual contingencies as of the acquisition date.

The Group allocates the fair value of purchase consideration to the tangible assets acquired, liabilities assumed and intangible assets acquired based on their estimated fair values. The excess of the fair value of purchase consideration over the fair values of these identifiable assets and liabilities is recorded as goodwill. Such valuations require management to make significant estimates and assumptions, especially with respect to intangible assets. Significant estimates in valuing certain intangible assets may include, but are not limited to, future expected cash flows from acquired assets, timing and probability of success of clinical events and regulatory approvals, and assumptions on useful lives of the patents and discount rates. Management’s estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. Additional information, such as that related to income tax and other contingencies, existing as of the acquisition date but unknown to us may become known during the remainder of the measurement period, not to exceed one year from the acquisition date, which may result in changes to the amounts and allocations recorded.

Acquisitions that do not meet the accounting definition of a business combination are accounted for as asset acquisitions. For transactions determined to be asset acquisitions, the Group allocates the total cost of the acquisition, including transaction costs, to the net assets acquired based on their relative fair values.

2.24 Segment information

In accordance with ASC 280, Segment Reporting, the Group’s chief operating decision maker, the Chief Executive Officer, reviews the consolidated results when making decisions about allocating resources and assessing performance of the Group as a whole and hence, the Group has only one reportable segment. The Group does not distinguish between markets or segments for the purpose of internal reporting. As the Group’s long-lived assets are substantially located in and derived from the PRC, no geographical segments are presented.

F-20

Table of Contents

I-MAB

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

(All amounts in thousands, except for share and per share data, unless otherwise noted)

2. PRINCIPAL ACCOUNTING POLICIES (CONTINUED)

2.25 Loss per share

Basic loss per share is computed by dividing net loss attributable to ordinary shareholders by the weighted average number of ordinary shares outstanding during the period using the two-class method. Under the two-class method, the net loss is allocated between ordinary shares and other participating securities based on their participating rights. Net loss is not allocated to other participating securities if based on their contractual terms they are not obligated to share in the loss. Diluted loss per share is calculated by dividing net loss attributable to ordinary shareholders by the weighted average number of ordinary and dilutive ordinary equivalent shares outstanding during the period. Ordinary equivalent shares consist of shares issuable upon the conversion of the preferred shares using the if-converted method, shares issuable upon the issuance of ordinary shares to be issued to Everest using the if-converted method, shares issuable upon the conversion of the convertible promissory notes using the if-converted method, shares issuable upon the exercise of share options using the treasury stock method, shares issuable upon the issuance of ordinary shares for restricted shares units using the treasury stock method, and shares issuable upon the exercise of warrants using the treasury stock method. Ordinary equivalent shares are not included in the denominator of the diluted loss per share calculation when inclusion of such shares would be anti-dilutive.

2.26 Adopted accounting pronouncements

In March 2020, the FASB issued ASU 2020-04, “Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting”, which provides optional expedients and exceptions for applying U.S. GAAP on contract modifications and hedge accounting to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform, if certain criteria are met. These optional expedients and exceptions provided in ASU 2020-04 are effective for the Company as of March 12, 2020 through December 31, 2022. The Company adopted this from January 1, 2022, which did not have a material impact on the Group’s consolidated financial statements.

In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt — Modifications and Extinguishments (Subtopic 470-50), Compensation — Stock Compensation (Topic 718), and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40) to clarify and reduce diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in this update are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. The Company adopted this from January 1, 2022, which did not have a material impact on the Group’s consolidated financial statements.

In July 2021, the FASB issued ASU 2021-05, Lessors—Certain Leases with Variable Lease (“ASU 2021-05”). It requires lessors to classify leases as operating leases if they have variable lease payments that do not depend on an index or rate and would have selling losses if they were classified as sales-type or direct financing leases. The Company adopted this from January 1, 2022, which did not have a material impact on the Group’s consolidated financial statements.

In June 2022, the FASB issued ASU 2022-03, “Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions”, which clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. The amendments also clarify that an entity cannot, as a separate unit of account, recognize and measure a contractual sale restriction. This guidance also requires certain disclosures for equity securities subject to contractual sale restrictions. The new guidance is required to be applied prospectively with any adjustments from the adoption of the amendments recognized in earnings and disclosed on the date of adoption. This guidance is effective for the Company for the year ending March 31, 2025 and interim reporting periods during the year ending March 31, 2025. Early adoption is permitted. The Company does not expect that the adoption of this guidance will have a material impact on the financial position, results of operations and cash flows.

F-21

Table of Contents

I-MAB

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

(All amounts in thousands, except for share and per share data, unless otherwise noted)

2. PRINCIPAL ACCOUNTING POLICIES (CONTINUED)

2.27 Recent accounting pronouncements

In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805) — Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”). It requires issuers to apply ASC 606 Revenue from Contracts with Customers to recognize and measure contract assets and contract liabilities from contracts with customers acquired in a business combination. ASU 2021-08 is effective for the Company from January 1, 2023, with early adoption permitted. The ASU is currently not expected to have a material impact on the Group’s consolidated financial statements.

3. ACCOUNTS RECEIVABLE AND CONTRACT ASSETS

Accounts receivable and contract assets, net of allowance for credit losses, consisted of the following:

    

As of December 31,

As of June 30, 

2021

2022

    

RMB

    

RMB

    

US$ (Note 2.5)

Accounts receivable, gross

 

33,081

 

510

 

76

Allowance for credit losses

 

 

 

Accounts receivable, net

 

33,081

 

510

 

76

    

As of December 31,

As of June 30, 

2021

2022

    

RMB

    

RMB

    

US$ (Note 2.5)

Contract assets, gross

 

253,780

 

291,079

 

43,457

Allowance for credit losses

 

 

 

Contract assets, net

 

253,780

 

291,079

 

43,457

No allowance for credit losses was recorded as of December 31, 2021 and June 30, 2022.

F-22

Table of Contents

I-MAB

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

(All amounts in thousands, except for share and per share data, unless otherwise noted)

4. Inventories

Inventories consist of the following:

    

As of December 31,

As of June 30, 

2021

2022

    

RMB

    

RMB

    

US$ (Note 2.5)

Investigational products

 

27,237

 

 

In April 2021, the Group entered into a master clinical supply agreement with AbbVie. Inc for the supply of investigational products for use in the clinical trials. For the year ended December 31, 2021, the Group recognized revenue of RMB47,911 for the products delivered to AbbVie. Inc. The inventories balance as of December 31, 2021 represented the investigational products that have been produced by the contract manufacturer and transferred control to the Group. For the six months ended June 30, 2021 and 2022, the Group recognized revenue of nil and RMB28,102 for the products delivered to AbbVie. Inc, respectively.

5. PREPAYMENTS AND OTHER RECEIVABLES